MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
Aptevo Therapeutics Operating Cycle 2011-2026 | APVO
Annual Operating Cycle Aptevo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 191 | 141 | 128 | 143 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 191 | 128 | 151 |
Quarterly Operating Cycle Aptevo Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 244 | 168 | 144 | - | 149 | 134 | 155 | - | 31.6 | 18.1 | 52.1 | 3.19 | 74.4 | 38.4 | 60.7 | 71.1 | 89.8 | 41.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 244 | 3.19 | 92.2 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
127 | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
237 | $ 21.47 | 0.51 % | $ 1 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
61.7 | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Akebia Therapeutics
AKBA
|
210 | $ 1.53 | 3.74 % | $ 393 M | USA |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.83 | 0.91 % | $ 27.9 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.13 | -1.43 % | $ 442 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 25.25 | 4.68 % | $ 3.21 B | USA |
 |
Chimerix
CMRX
|
588 | - | - | $ 756 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
321 | $ 33.25 | 2.03 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.49 | 1.02 % | $ 397 M | Britain |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |